MAIA Biotechnology, Inc.
For the period ended Dec 31, 2024. Filed Mar 21, 2025.
View on SEC.govAbout this filing
A company's yearly report to the SEC, with audited financial statements. It is the fullest account a company gives of its business, its finances and the risks it sees.
FY2024 · Filed Mar 21, 2025
MAIA$1.05-3.7%Stored close · as of Nov 10, 2026
Extracted filing text, with the paragraph anchors used by the comparison.
See the whole filing, with its images and exhibitsContents
Item 8. Consolidated Statements of Cash Flows
Consolidated Statements of Cash Flows
| Years Ended December 31, | ||
|---|---|---|
| 2024 | 2023 | |
| Cash flows from operating activities: | ||
| Net loss | $(23,254,656) | $(19,772,905) |
| Adjustments to reconcile net loss to net cash used in operating activities: | ||
| Stock-based compensation | 1,912,744 | 3,089,304 |
| Consulting expense for restricted shares issued | 179,490 | 731,661 |
| Change in fair value of warrant liability | 6,682,758 | (205,130) |
| Loss on fair value of warrants over proceeds | 12,952 | — |
| Change in operating assets and liabilities: | ||
| Prepaid expenses and other current assets | (195,935) | 285,831 |
| Australia research and development incentives receivable | 56,805 | 158,405 |
| Accounts payable | (118,827) | 471,897 |
| Accrued expenses | (979,792) | 2,169,921 |
| Net cash used in operating activities | (15,704,461) | (13,071,016) |
| Cash flows from financing activities: | ||
| Proceeds from exercise of stock options | 217,158 | 1,432 |
| Proceeds from sale of common stock in follow-on offering | — | 5,749,875 |
| Proceeds from direct offering | — | 4,000,001 |
| Proceeds from private placement round 1 | 2,920,696 | — |
| Proceeds from private placement round 2 | 1,327,990 | — |
| Proceeds from private placement round 3 | 1,004,999 | — |
| Proceeds from private placement round 4 | 2,439,236 | — |
| Proceeds from private placement round 5 | 949,791 | — |
| Proceeds from At-The-Market offering | 10,111,996 | 1,667,084 |
| Payment of offering transactions costs | (795,257) | (2,147,491) |
| Net cash provided by financing activities | 18,176,609 | 9,270,901 |
| Net effect of foreign currency exchange on cash | (21,545) | (117) |
| Net increase (decrease) in cash | 2,450,603 | (3,800,232) |
| Cash at beginning of period | 7,150,695 | 10,950,927 |
| Cash at end of period | $9,601,298 | $7,150,695 |
| Supplemental disclosure of cash flow information: | ||
| Options issued for accrued bonus | $— | $974,224 |
| Warrants issued to underwriters in connection with the follow-on offering | $— | $241,109 |
| Warrants issued in connection with the At-The-Market offering | $— | $84,251 |
| Warrants issued in connection with the direct offering | $— | $1,903,915 |
| Warrants issued to underwriters in connection with the direct offering | $— | $123,811 |
| Warrants issued with private placement 1 offering | $2,049,600 | $— |
| Warrants issued with private placement 2 offering | $1,190,111 | $— |
| Warrants issued with private placement 3 offering | $677,919 | $— |
| Warrants issued with private placement 4 offering | $1,800,389 | $— |
| Warrants issued with private placement 5 offering | $635,345 | $— |
The text of this filing, as the company filed it with the SEC, without its images or exhibits. This is not investment advice.